Profit-taking on good news
Despite a stream of positive headlines around Zepbound head-to-head data and its oral GLP-1 pill, the stock is drifting down moderately on normal volume, which looks like profit-taking after a strong news run rather than a reaction to any negative catalyst.
Sources: https://www.gurufocus.com/news/eli-lillys-zepbound-shows-superior-weight-loss-vs-wegovy-hd-b
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works